Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy

Neoplasma

Volumn 60, Issue 2, 2013, Pages 129-134

  Fiala, O ^a   Pesek, M ^a   Finek, J ^a   Krejci, J ^b   Bortlicek, Z ^c   Benesova, L ^d   Minarik, M ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d Genomac Research Institute   (Czech Republic)

Author keywords

EGFR TKI; Erlotinib; NSCLC; Targeted treatment of NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE CONTROL; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SMOKING; TREATMENT RESPONSE; GENETICS; LUNG TUMOR; MORTALITY; MUTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84878895883     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_017     Document Type: Article

References (28)

1. LYNCH TJ, BELL DW, SORDELLA R, GURUBHAGAVATULA S, OKIMOTO RA et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib., N Engl J Med. 2004; 350: 2129-39. http://dx.doi.org/10.1056/NEJMoa040938
2. PAEZ JG, JANNE PA, LEE JC, TRACY S, GREULICH H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500. http://dx.doi.org/10.1126/science.1099314
3. GANDHI J, ZHANG J, XIE Y, SOH J, SHIGEMATSU H et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One. 2009; 4: e4576. http://dx.doi.org/10.1371/journal.pone.0004576
4. MINARIK M, BENESOVA L, BELSANOVA B, MUKENSNABL P, BRUHA F et al. Effect of mutations in EGFR and KRAS genes in the prognosis of survival in patients with NSCLC treated with inhibitors of tyrosine-kinase (comparison of results of treatment with erlotinib and gefitinib). Studia pneumologica et phtiseologica. 2009; 69: 96-104.
5. EBERHARD DA, JOHNSON BE, AMLER LC, GODDARD AD, HELDENS SL et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5900-9. http://dx.doi.org/10.1200/JCO.2005.02.857
6. BONANNO L, SCHIAVON M, NARDO G, BERTORELLE R, BONALDI L et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res. 2010; 30: 5121-8.
7. LIU HP, ISAAC WU HD, CHANG JW, WU YC, YANG HY et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol. 2010; 5: 1175-84. http://dx.doi.org/10.1097/JTO.0b013e3181e2f4d6
8. ZHU CQ, DA CUNHA SANTOS G, DING K, SAKURADA A, CUTZ JC et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26: 4268-75. http://dx.doi.org/10.1200/JCO.2007.14.8924
9. HIRSCH FR, VARELLA-GARCIA M, BUNN PA JR, FRANKLIN WA, DZIADZIUSZKO R et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5034-42. http://dx.doi.org/10.1200/JCO.2006.06.3958
10. DOUILLARD JY, SHEPHERD FA, HIRSH V, MOK T, SOCINSKI MA et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010; 28: 744-52. http://dx.doi.org/10.1200/JCO.2009.24.3030
11. CAPPUZZO F, CIULEANU T, STELMAKH L, CICENAS S, SZCZESNA A et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-9. http://dx.doi.org/10.1016/S1470-2045(10)70112-1
12. BRUGGER W, TRILLER N, BLASINSKA-MORAWIEC M, CURESCU S, SAKALAUSKAS R et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol. 2009; 27:15s, (suppl; abstr 8020)
13. PESEK M, BENESOVA L, BELSANOVA B, MUKENSNABL P, BRUHA F et al. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res. 2009; 29: 2767-73.
14. FUKUOKA M, WU YL, THONGPRASERT S, SUNPAWERAVONG P, LEONG SS et al. Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29: 2866-74. http://dx.doi.org/10.1200/JCO.2010.33.4235
15. ZHOU C, WU YL, CHEN G, FENG J, LIU XQ et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-42. http://dx.doi.org/10.1016/S1470-2045(11)70184-X
16. ROSELL R, CARCERENY E, GERVAIS R, VERGNENEGRE A, MASSUTI B et al. Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46 http://dx.doi.org/10.1016/S1470-2045(11)70393-X
17. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer V.3.2011.
18. HEIGENER DF, WU YL, VAN ZANDWIJK N, MALI P, HORWOOD K et al. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer. 2011; 74: 274-9. http://dx.doi.org/10.1016/j.lungcan.2011.02.017
19. MELOSKY B, AGULNIK J, ASSI H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol. 2008; 15: 279-85. http://dx.doi.org/10.3747/co.v15i6.382
20. CASTAGNARI A. Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option., BMC Proc. 2008; 2 Suppl 2: S4.
21. RECK M, VAN ZANDWIJK N, GRIDELLI C, BALIKO Z, RISCHIN D et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010; 5: 1616-22. http://dx.doi.org/10.1097/JTO.0b013e3181f1c7b0
22. MOK T, WU YL, AU JS, ZHOU C, ZHANG L et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer., J Thorac Oncol. 2010; 5: 1609-15. http://dx.doi.org/10.1097/JTO.0b013e3181e15d55
23. KUBOTA K, NISHIWAKI Y, TAMURA T, NAKAGAWA K, MATSUI K et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol. 2008; 3: 1439-45. http://dx.doi.org/10.1097/JTO.0b013e31818d6702
24. AGERO AL, DUSZA SW, BENVENUTO-ANDRADE C, BUSAM KJ, MYSKOWSKI P et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors., J Am Acad Dermatol. 2006; 55: 657-70. http://dx.doi.org/10.1016/j.jaad.2005.10.010
25. SANDLER AB. Nondermatologic adverse events associated with anti-EGFR therapy., Oncology (Williston Park). 2006; 20 (5 Suppl 2): 35-40.
26. THERASSE P, ARBUCK SG, EISENHAUER EA, WANDERS J, KAPLAN RS et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3): 205-16. http://dx.doi.org/10.1093/jnci/92.3.205
27. FORBES SA, BHAMRA G, BAMFORD S, DAWSON E, KOK C et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11.
28. SHUKUYA T, TAKAHASHI T, KAIRA R, ONO A, NAKAMURA Y et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 2011; 102(5): 1032-7. http://dx.doi.org/10.1111/j.1349-7006.2011.01887.x